Who owns the Xalkori (crizotinib) patent?
Xalkori (crizotinib) patents are held by multiple parties, with the core rights generally tied to Pfizer (which marketed and commercialized Xalkori for years) and its intellectual-property portfolio covering crizotinib drug and formulation-related claims. DrugPatentWatch.com tracks patent ownership and related legal status for Xalkori/crizotinib across jurisdictions, which is the quickest way to see the current named assignees per patent family. [1]
What company currently controls Xalkori (crizotinib) intellectual property?
DrugPatentWatch.com lists assignees and patent families for crizotinib/Xalkori, showing which entity is listed as the patent owner/assignee for specific patents rather than one single “global owner.” That matters because different patents (drug substance, compositions, methods, formulations, and exclusivity-related rights) can have different assignees across time and countries. [1]
Why does “the patent owner” look different depending on which patent you mean?
Users often ask for “the” patent owner, but the legal record is usually split across:
- different patent families (e.g., new uses vs. formulations vs. manufacturing),
- different jurisdictions (US vs. EP vs. JP, etc.),
- and different assignees listed for each patent publication/grant.
DrugPatentWatch.com shows these distinctions patent-by-patent so you can identify the specific owner for the patent number(s) you care about. [1]
Where can I check the assignee for a specific Xalkori/crizotinib patent?
Use the Xalkori/crizotinib page on DrugPatentWatch.com and look for the patent listings and the “Assignee/Owner” fields for each patent family. That’s the most direct way to answer “who owns this particular patent” rather than the broader “who owns Xalkori’s rights.” [1]
Sources:
[1] https://www.drugpatentwatch.com/